Company Flamel Technologies S.A. (ADR) Nasdaq

US3384881096

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Managers	Title	Age	Since
Gregory Divis CEO	Chief Executive Officer	57	17-01-02
Thomas McHugh DFI	Director of Finance/CFO	59	19-12-01
Scott Macke COO	Chief Operating Officer	-	14-08-31
Jerad G. Seurer CMP	Compliance Officer	-	16-12-31
Jennifer Gudeman CTO	Chief Tech/Sci/R&D Officer	-	20-12-06
Jason Vaughn CTO	Chief Tech/Sci/R&D Officer	-	19-12-01
Denise Strauss SAM	Sales & Marketing	-	21-06-01
Angela Woods HRO	Human Resources Officer	-	21-04-30
Richard Kim PRN	Corporate Officer/Principal	54	21-02-14

Members of the board	Title	Age	Since
Eric Ende BRD	Director/Board Member	55	18-11-30
Gregory Divis CEO	Chief Executive Officer	57	17-01-02
Mark McCamish BRD	Director/Board Member	72	19-12-04
Geoffrey Glass CHM	Chairman	50	18-06-30
Linda Palczuk BRD	Director/Board Member	62	18-06-30
Peter Thornton BRD	Director/Board Member	59	17-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	90,576,998	86,139,858 ( 95.10 %)	0	95.10 %
Stock B	0	5,194,000	0	0

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 6.141 %	11,125,330	6.141 %	188 M $
The Lind Partners LLC 5.299 %	9,599,250	5.299 %	162 M $
RTW Investments LP 3.835 %	6,947,918	3.835 %	117 M $
POLAR CAPITAL HOLDINGS PLC 3.727 %	6,751,782	3.727 %	114 M $
Tontine Associates LLC 3.100 %	5,615,350	3.100 %	95 M $
Vivo Capital LLC 2.261 %	4,096,428	2.261 %	69 M $
Kevin Kotler 2.051 %	3,716,242	2.051 %	63 M $
Wealth Effects LLC 1.334 %	2,416,326	1.334 %	41 M $
Woodline Partners LP 1.023 %	1,852,412	1.023 %	31 M $
Cowen & Co. LLC 0.9066 %	1,642,347	0.9066 %	28 M $

Name	Equities	%	Valuation
RTW Investments LP 100.00 %	487,614	100.00 %	8 M $

Avadel Pharmaceuticals Plc

10 Earlsfort Terrace

02, Dublin

+353 1 901 5201

http://www.avadel.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.58%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.96%	211B
NOVARTIS AG	-0.41%	203B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals